Fisetin ameliorates fibrotic kidney disease in mice via inhibiting ACSL4-mediated tubular ferroptosis

Bo Wang(West China Hospital of Sichuan University), Lina Yang(West China Hospital of Sichuan University), Letian Yang(Sichuan University), Yan Liang(Sichuan University), Fan Guo(Sichuan University), Ping Fu(West China Hospital of Sichuan University), Liang Ma(West China Hospital of Sichuan University)
Acta Pharmacologica Sinica
September 11, 2023
10.1038/s41401-023-01156-w
Cited by 112Open Access
Full Text

Abstract

Related Papers

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Sebastian Doll, Bettina Proneth, Yulia Y. Tyurina et al.|Nature Chemical Biology|2016|4k
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
Kyle J Foreman, Neal Marquez, Andrew J. Dolgert et al.|The Lancet|2018|2.9k
Cellular and molecular mechanisms of renal fibrosis
Youhua Liu|Nature Reviews Nephrology|2011|1.4k
Renal fibrosis: New insights into the pathogenesis and therapeutics
Youhua Liu|Kidney International|2006|1.1k
Identification of ACSL4 as a biomarker and contributor of ferroptosis
Hua Yuan, Xuemei Li, Xiuying Zhang et al.|Biochemical and Biophysical Research Communications|2016|1.1k